JP2016534023A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534023A5
JP2016534023A5 JP2016515409A JP2016515409A JP2016534023A5 JP 2016534023 A5 JP2016534023 A5 JP 2016534023A5 JP 2016515409 A JP2016515409 A JP 2016515409A JP 2016515409 A JP2016515409 A JP 2016515409A JP 2016534023 A5 JP2016534023 A5 JP 2016534023A5
Authority
JP
Japan
Prior art keywords
hydroxy
propan
pyrrolidin
oxoacetamide
dioxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515409A
Other languages
English (en)
Japanese (ja)
Other versions
JP6537500B2 (ja
JP2016534023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/056555 external-priority patent/WO2015042397A1/en
Publication of JP2016534023A publication Critical patent/JP2016534023A/ja
Publication of JP2016534023A5 publication Critical patent/JP2016534023A5/ja
Application granted granted Critical
Publication of JP6537500B2 publication Critical patent/JP6537500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515409A 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤 Active JP6537500B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361880752P 2013-09-20 2013-09-20
US61/880,752 2013-09-20
PCT/US2014/056555 WO2015042397A1 (en) 2013-09-20 2014-09-19 Glucosylceramide synthase inhibitors for the treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019104161A Division JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016534023A JP2016534023A (ja) 2016-11-04
JP2016534023A5 true JP2016534023A5 (https=) 2017-11-02
JP6537500B2 JP6537500B2 (ja) 2019-07-03

Family

ID=51794951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Country Status (10)

Country Link
US (2) US10227323B2 (https=)
EP (2) EP3912977A1 (https=)
JP (2) JP6537500B2 (https=)
CN (2) CN110372636B (https=)
AU (2) AU2014321397C1 (https=)
CA (1) CA2924545C (https=)
IL (2) IL244628B (https=)
MX (1) MX374452B (https=)
TW (2) TWI690511B (https=)
WO (1) WO2015042397A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
US11744396B1 (en) * 2015-11-10 2023-09-05 Caffeine Innovations, LLC System, method, and device for agitating coffee grounds
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN107216238A (zh) * 2016-03-21 2017-09-29 湖南师范大学 醇镁法制备4-甲基儿茶酚
ES2831086T3 (es) * 2016-09-02 2021-06-07 Igm Group B V Glioxilatos policíclicos como fotoiniciadores
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
WO2018177781A1 (en) 2017-03-28 2018-10-04 Basf Se Pesticidal compounds
ES3039587T3 (en) 2017-12-21 2025-10-22 Basf Se Pesticidal compounds
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
TWI877182B (zh) * 2019-07-01 2025-03-21 美商古拉森療法公司 β腎上腺素激動劑及其使用方法
JP7539382B2 (ja) * 2019-07-29 2024-08-23 武田薬品工業株式会社 複素環化合物
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
EP4048397B1 (en) * 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors for therapeutic applications
AU2020384066B2 (en) * 2019-11-15 2025-10-30 Green Cross Corporation Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
US20230002380A1 (en) * 2019-11-15 2023-01-05 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
EP4142878B1 (en) 2020-04-28 2024-06-26 The Regents of The University of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113912544B (zh) * 2021-11-29 2023-03-17 沧州普瑞东方科技有限公司 一种5-溴-1-甲基吲唑的制备方法
JP2025527600A (ja) * 2022-08-18 2025-08-22 エースリンク・セラピューティクス・インコーポレイテッド グルコシルセラミド合成酵素阻害薬の結晶形及びその使用
CN115433157B (zh) * 2022-11-09 2023-02-07 苏州凯瑞医药科技有限公司 一种依利格鲁司特中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
ATE383153T1 (de) 1999-05-07 2008-01-15 Encysive Pharmaceuticals Inc Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
WO2002080920A1 (en) 2001-04-06 2002-10-17 Axys Pharmaceuticals, Inc. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
EP2067775B1 (en) 2001-07-16 2012-04-25 Genzyme Corporation A N-Acylsphingosine glucosyltransferase inhibitor
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
WO2003057874A1 (fr) 2001-12-28 2003-07-17 Sumitomo Pharmaceuticals Company, Limited Marqueurs de maladies pour maladies renales et leur utilisation
WO2004080960A2 (en) 2003-03-06 2004-09-23 Neose Technologies Inc. Methods and compositions for the enzymatic synthesis of gangliosides
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
DE602005020465D1 (de) * 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
US20090088433A1 (en) 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
WO2008109286A1 (en) 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
CN101888840A (zh) * 2007-10-05 2010-11-17 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
MY156662A (en) 2007-11-01 2016-03-15 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
WO2009099736A2 (en) * 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
CA3140959A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US8961959B2 (en) * 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014150043A1 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Similar Documents

Publication Publication Date Title
JP2016534023A5 (https=)
JP2019182869A5 (https=)
US10913727B2 (en) Modulators of the integrated stress pathway
TWI432431B (zh) 調控c-fms及/或c-kit活性之化合物及其用途
JP6385954B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
JP4310109B2 (ja) ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
TWI567067B (zh) TrK抑制化合物
RU2586974C2 (ru) Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств
US9862716B2 (en) TRKA kinase inhibitors, compositions and methods thereof
Peifer et al. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1 H-indole-3yl)-1, 5-dihydro-2 H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors
US11155557B2 (en) Pyrazolopyrimidine compounds and methods of use thereof
IL303196B1 (en) Heteroaryl substituted pyridines and methods of use
JP2016517878A5 (https=)
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
RU2019132212A (ru) Селективные ингибиторы hdac6
TW201718597A (zh) Hpk1抑制劑及其使用方法
JP7034512B2 (ja) キナーゼ阻害剤としてのヘテロアリール化合物
JP2010513444A5 (https=)
JP7744350B2 (ja) 置換ピラゾロ-ピリミジンおよびその使用
BG108013A (bg) Заместени аминопроизводни и методи за използването им
NZ630124A (en) Estrogen receptor modulators and uses thereof
ES2342783T3 (es) Aril aciltioureas sustituidas y compuestos relacionados, inhibidores de la replicacion viral.
MX2014013011A (es) Compuesto heterociclico nitrogenado.
JP2017530185A5 (https=)
KR20140041609A (ko) 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체